.jpg?w=340&itok=_weN-aN8 "IPT discussed in technical publications."){kind=icon}
Biologic viral safety is entering a new phase. Updated global ICH guidance is reshaping how manufacturers approach risk based controls, modern analytics and manufacturing innovation. In this PharmTech feature, John M. e...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Pfizer COVID vaccine trial proved remote monitoring, other innovations work, ICON CEO says
ICON CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
-
Decentralised & hybrid trials: The future of clinical trials post pandemic
An interview with EB McLindon, Senior VP, Patient, Site & Decentralised Solutions, on why the future of drug development involves decentralising parts of the clinical trial process.
-
Moving from on-site" to agile: The changing dynamic in study management"
Pharmafocus (pages 16-17) features a thought leadership piece by Rose Kidd which examines the benefits of agile clinical monitoring in study management.
-
Clinical trials shift to hybrid approaches in the age of COVID-19 and beyond
An article examining the state of clinical trials for orthopedics, featuring expert commentary from ICON's David T. Novotny, General Manager & Global Head, Medical Device & Diagnostic Research.
-
Engaging the crowds
A thought leadership piece by Peter Schueler which considers the importance of patient engagement and enrollment in Alzheimer's clinical trials.
This article is taken from International Clinical Trials November 2020, pages 10-12. © Samedan Ltd.
-
.jpg?w=545&itok=WjjDeARM "IPT discussed in technical publications.")
Data capture in a post-digital clinical trial landscape
A thought leadership article authored by Tom O’Leary on how collected data from digital health technologies, coupled with novel clinical trial models, have the ability to increase the value proposition of drugs and medical devices.
This article is taken from Innovations in Pharmaceutical Technology Autumn/Winter 2020, pages 38-40. © Samedan Ltd
-
The quest for increased efficiency in personalised medicine clinical trials
A thought leadership piece by Lawrence Johnson and Cynthia Spittle discussing personalised medicine and how digital devices can improve treatment across a wide spectrum of conditions (pages 16-17).
-
BARDA reselects ICON as preferred partner
An article focused on the BARDA announcement that ICON continues to be a part of The Clinical Trials Planning and Execution component of the CSN, responsible for planning and executing clinical studies to support medical countermeasure development.
-
AI in Life Sciences – Covid pushes AI driven clinical trials and drug manufacturing into the limelight
ICON’s CIO, Tom Leary discusses the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
-
Navigating cell therapy manufacturing amid pandemic woes
An article featuring expert commentary from ICON's Tamie Joeckel on supply-chain strategies to help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
